ALUNBRIG Approved by European Commission as Treatment for Patients with ALK+ NSCLC
kalhh / Pixabay

ALUNBRIG Approved by European Commission as Treatment for Patients with ALK+ NSCLC

  According to a release on Biospace, the European Commission (EC) has approved Takeda Pharmaceutical's ALUNBRIG (brigatinib) as treatment for patients with anaplastic lymphoma kinase-positive (ALK+) advanced non-small cell lung cancer…

Continue Reading ALUNBRIG Approved by European Commission as Treatment for Patients with ALK+ NSCLC
EMA Recommends ALUNBRIG for the Treatment of Non-Small Cell Lung Cancer
oracast / Pixabay

EMA Recommends ALUNBRIG for the Treatment of Non-Small Cell Lung Cancer

The European Medicines Agency has recently released their positive opinion of ALUNBRIG, which is a treatment for anaplastic lymphoma kinase+ (ALK+) non-small cell lung cancer (NSCLC). They have recommended this…

Continue Reading EMA Recommends ALUNBRIG for the Treatment of Non-Small Cell Lung Cancer

A New Approach to Halting Metastatic Cancer

A recent article in Northwestern's University Health reported that although the survival rate for cancer patients has vastly improved over the past twenty years, the deaths due to metastatic cancer…

Continue Reading A New Approach to Halting Metastatic Cancer

ICYMI: With the FDA’s Third Approval for Tissue Agnostic Therapies, Oncologists are Headed to the Next Level in Cancer Treatment

Since the 1940s oncologists have been focusing on tumors at the location in the body where the tumors originated. According to a recent FDA press release, this is the third…

Continue Reading ICYMI: With the FDA’s Third Approval for Tissue Agnostic Therapies, Oncologists are Headed to the Next Level in Cancer Treatment

The Impact of Patient Registries on Research and How You Can Join

  A recent article published in Curetoday highlights not only the many new and successful therapies available to cancer patients but it also illustrates how patients can connect to other…

Continue Reading The Impact of Patient Registries on Research and How You Can Join

New Treatment Approved by FDA for Rare Form of Hepatocellular Carcinoma

The FDA has just recently approved CYRAMZA as a treatment for those with hepatocellular carcinoma (HCC), who have been treated with sorafenib, and who have ≥400 ng/mL of alpha-fetoprotein (AFP).…

Continue Reading New Treatment Approved by FDA for Rare Form of Hepatocellular Carcinoma

New Partnership will Improve and Accelerate Patient Involvement in Lung Cancer Research

Pattern.Org Pattern.org was created by the Rare Cancer Research Foundation, a nonprofit dedicated to improving the lives of rare cancer patients by accelerating research. Pattern.org specifically, is a branch of…

Continue Reading New Partnership will Improve and Accelerate Patient Involvement in Lung Cancer Research
Close Menu